Brokerages expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report ($0.39) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for PTC Therapeutics’ earnings, with estimates ranging from ($0.49) to ($0.28). PTC Therapeutics reported earnings per share of ($0.09) during the same quarter last year, which would suggest a negative year over year growth rate of 333.3%. The firm is scheduled to announce its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that PTC Therapeutics will report full year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($2.91) to ($2.05). For the next year, analysts expect that the firm will post earnings of ($1.56) per share, with EPS estimates ranging from ($1.73) to ($1.38). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow PTC Therapeutics.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.55). PTC Therapeutics had a negative net margin of 68.99% and a negative return on equity of 32.42%. The firm had revenue of $53.58 million for the quarter, compared to the consensus estimate of $70.38 million. During the same period last year, the company posted ($0.46) earnings per share. PTC Therapeutics’s revenue for the quarter was down 4.4% on a year-over-year basis.

Several research firms recently issued reports on PTCT. Citigroup set a $59.00 price objective on PTC Therapeutics and gave the company a “buy” rating in a research note on Friday, May 3rd. Zacks Investment Research downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Cantor Fitzgerald reissued a “buy” rating and issued a $61.00 target price on shares of PTC Therapeutics in a research note on Thursday, February 28th. ValuEngine cut PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Sanford C. Bernstein started coverage on PTC Therapeutics in a research note on Thursday, April 11th. They issued an “outperform” rating and a $48.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. PTC Therapeutics has a consensus rating of “Buy” and an average target price of $49.89.

Shares of PTC Therapeutics stock traded down $1.43 during trading hours on Friday, reaching $40.27. The company had a trading volume of 10,736 shares, compared to its average volume of 781,656. PTC Therapeutics has a one year low of $27.53 and a one year high of $52.95. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.35 and a quick ratio of 3.24. The firm has a market capitalization of $2.39 billion, a P/E ratio of -21.82 and a beta of 1.79.

In other PTC Therapeutics news, COO Marcio Souza sold 5,490 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $40.38, for a total transaction of $221,686.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.00% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of PTCT. NumerixS Investment Technologies Inc purchased a new stake in shares of PTC Therapeutics in the 4th quarter worth $32,000. Canton Hathaway LLC increased its stake in shares of PTC Therapeutics by 57.1% in the 4th quarter. Canton Hathaway LLC now owns 1,100 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 400 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of PTC Therapeutics by 283.2% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,395 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,031 shares in the last quarter. Botty Investors LLC purchased a new stake in shares of PTC Therapeutics in the 1st quarter worth $75,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PTC Therapeutics by 34.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,732 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 696 shares in the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Featured Article: Roth IRA

Get a free copy of the Zacks research report on PTC Therapeutics (PTCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.